Coca Leaf Extract Blocked Weight Gain in Mice, Magdalena Says

A joint venture between Jaguar Health and Filament Health Corp says a coca leaf extract prevented weight gain in mice fed a high-fat diet, without cutting how much the animals ate or making them move more. The announcement, reported by scanx.trade, positions the extract as a prescription drug candidate for people who have stopped taking GLP-1 weight-loss medications.

The venture, Magdalena Biosciences, states that the candidate will be developed under the U.S. Food and Drug Administration’s Botanical Guidance — the regulatory pathway used for drugs made from plant material rather than a single synthesized molecule.

scanx.trade reports the preclinical work ran 20 days at the University of Calgary in Alberta, Canada. This is animal data at an early stage, and no human trial, filing date or approval timeline has been stated.

What the mouse study reported

The stated result is narrow but specific: mice on a high-fat diet did not gain weight, and the company says that happened without a drop in food intake or a rise in physical activity. That combination is what makes the finding interesting, because appetite suppression is the mechanism most people associate with weight drugs.

The post-GLP-1 problem it targets

GLP-1 drugs reduce appetite and increase fullness while a patient is taking them. When the drug stops, those effects fade and body weight commonly climbs back — the rebound that Magdalena says its candidate is meant to address as a maintenance therapy.

• Magdalena Biosciences was formed in 2023 by Jaguar Health, based in the US, and Filament Health Corp, based in Canada.
• Its stated focus is plant-derived prescription medicines for mental health and central nervous system indications, now extended to weight maintenance.
• One Small Planet, founded by Will Peterffy, has committed US$1,000,000 in funding to the venture.
• Steven King, PhD, of Jaguar Health said a coca extract drug developed under the FDA’s Botanical Guidance is likely to carry low abuse potential.

Where the leaf came from, and why that detail counts

The coca leaf used in the research was supplied by Empresa Nacional de La Coca (ENACO), the Peruvian state coca company, which holds an Internationally Recognized Certificate of Compliance under Peru’s Nagoya Protocol requirements. That is the benefit-sharing framework governing access to genetic resources and traditional knowledge.

It matters because the underlying knowledge is not new. Andean peoples have chewed and brewed coca for centuries to manage hunger and fatigue, and a mouse study on appetite-independent weight regulation is, in effect, a laboratory testing something Indigenous communities have described for generations.

Why this matters

Our read: this is an early, modest data point, not a breakthrough, and it should be described that way. Twenty days in mice is a signal worth following, not evidence that anything works in people. Most compounds that clear a preclinical hurdle never reach a pharmacy shelf.

What is genuinely significant is the regulatory framing. A US venture openly building a prescription candidate from coca leaf, under an FDA botanical pathway, with legally sourced Peruvian leaf and a Nagoya-compliant certificate, is the kind of paperwork trail that has been almost impossible to assemble for this plant. The leaf is not cocaine, and a standardized whole-leaf extract is not a purified alkaloid — a distinction American drug policy has spent a century refusing to make.

Readers should also be clear about what this does not change. Coca leaf remains tightly controlled in the United States, and a company pursuing an FDA botanical drug application says nothing about the legal status of coca tea, chewing leaf, or imported leaf products. Nor does the low-abuse-potential comment from Jaguar’s Steven King represent a scheduling determination by any agency; it is a company view.

Still, the direction of travel is worth noting alongside the growing scientific literature we covered in the HerbalGram coca issue. When a plant moves from prohibition rhetoric into ethics-compliant supply chains and university labs, the argument shifts from ideology to data. That is where we have always wanted it.

Frequently Asked Questions

What did the Magdalena Biosciences coca leaf study actually find?

Magdalena Biosciences announced that a coca leaf extract prevented weight gain in mice fed a high-fat diet, and that it did so without reducing how much the mice ate or increasing their physical activity. The study ran 20 days at the University of Calgary in Alberta, Canada. These are preclinical animal results, not human findings.

Is the coca extract a cocaine product?

No. The candidate described by Magdalena Biosciences is an extract derived from coca leaves, which is a different thing from cocaine, a single purified alkaloid isolated and concentrated from the plant. Magdalena states the drug would be developed under the FDA's Botanical Guidance, the pathway for plant-derived medicines rather than single synthesized molecules.

Who is behind Magdalena Biosciences?

Magdalena Biosciences is a US-based joint venture formed in 2023 by Jaguar Health and Canada-based Filament Health Corp. Its stated aim is developing plant-derived prescription medicines, originally for mental health and central nervous system indications and now extended to weight maintenance. One Small Planet, founded by Will Peterffy, has committed US$1,000,000 in funding.

Why target people who have stopped taking GLP-1 drugs?

GLP-1 medications reduce appetite and increase feelings of fullness while a patient takes them, and weight often returns once treatment stops as hunger and body-weight regulation reassert themselves. Magdalena Biosciences says its coca leaf extract candidate is intended as a maintenance therapy for that post-GLP-1 period. Whether it works that way in people has not been established.

Where did the coca leaf for the research come from?

The coca leaf was supplied by Empresa Nacional de La Coca (ENACO), a Peruvian state company. ENACO holds an Internationally Recognized Certificate of Compliance in line with Peru's Nagoya Protocol requirements, the international framework governing access to genetic resources and associated traditional knowledge.

When could a coca extract weight-management drug be available?

No timeline has been stated. Magdalena Biosciences has announced only preclinical mouse results and an intention to develop the candidate under the FDA's Botanical Guidance, with no human trial dates, filing dates or approval schedule disclosed. Preclinical results are an early step and most candidates at that stage never reach patients.

Does this change the legal status of coca tea or coca leaf in the US?

No. A company pursuing an FDA botanical drug application for a coca leaf extract does not alter the legal status of coca leaf, coca tea or other leaf products in the United States. A comment from Jaguar Health's Steven King that such a drug would likely have low abuse potential is a company statement, not a scheduling decision by the DEA or any other agency.